Related Experiment Video
Updated: May 5, 2026
Assessment of the Metabolic Profile of Primary Leukemia Cells
Published on: November 21, 2018
Chronic leukemia
Edythe M Lyn Greenberg1, Alexandra Probst
1Department of Leukemia, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Insights
Chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) are distinct blood cancers. CML is treated with tyrosine kinase inhibitors, while CLL management varies from observation to targeted therapies.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Chronic leukemias encompass chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL).
- CML is characterized as a Philadelphia chromosome-positive myeloproliferative neoplasm.
- CLL presents as a monoclonal B-cell disorder with variable clinical courses.
Purpose of the Study:
- To provide an overview of the distinct characteristics of CML and CLL.
- To outline current therapeutic strategies for CML and CLL.
- To highlight the evolving landscape of targeted therapies for chronic leukemias.
Main Methods:
- Review of existing literature on CML and CLL.
- Analysis of diagnostic criteria and disease classifications.
- Summary of established and emerging treatment modalities.
Main Results:
- CML progresses through chronic, accelerated, and blast phases, primarily managed with tyrosine kinase inhibitors.
- CLL exhibits indolent or fulminant presentations, with early stages managed by observation.
- Current CLL treatments include chemotherapy and monoclonal antibodies, with ongoing development of targeted therapies.
Conclusions:
- CML and CLL represent distinct hematologic malignancies with different underlying mechanisms and treatment approaches.
- Tyrosine kinase inhibitors are the cornerstone of CML treatment.
- CLL management is individualized, with significant advancements in targeted therapies improving patient outcomes.
Abstract:
The chronic leukemias include chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL). CML is a clonal myeloproliferative hematopoietic stem-cell disorder, and CLL is a monoclonal B-cell disorder. CML is Philadelphia chromosome positive. There are 3 phases of CML: the chronic phase, the accelerated phase, and the blast phase. The primary treatment of CML consists of tyrosine kinase inhibitors. CLL can present as indolent or fulminant disease. Early disease is managed with observation. Fulminant disease is currently treated with alkylating agents, purine analogues, and monoclonal antibodies, but new biotarged therapies are being developed.
More Related Videos
Related Concept Videos
01:27Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
01:12Chronic Inflammation: Introduction
01:24Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
01:25Chronic Pancreatitis I: Introduction
01:25Chronic Kidney Disease I: Introduction
01:24Chronic Kidney Disease II: Clinical Manifestations